National and Kapodistrian University of Athens
Η μεταβολή της ιντερλευκίνης 1α και των αγγειοκινητικών πεπτιδίων κατά την εξέλιξη της συστηματικής σκλήρυνσης
Abstract
dc:descriptionIncreased concentrations of interleukin (IL)-1α have been recently described intissues of patients with systemic sclerosis (SSc), and this has been suggested to contribute to the pathogenesis of the disease. We conducted a double-blind, placebo -controlled study to assess the safety and efficacy of the fully humanized IL-1α blocking monoclonal antibody bermekimab in SSc. To evaluate response to treatment, we developed the score of inhibition of progression of SSc which was validated using the CRISS index and the modified CRISS index. The primary endpoint was met in 80% of bermekimab-treated patients vs 20% of placebo-treated patients (p: 0.023). Most of efficacy was found for the decrease of lung diffusion capacity. Bermekimab is a promising new candidate that could be efficacious in the treatment of SSc. Treatment with bermekimab was associated with monocyte modulation of cytokine production and attenuation of platelet activation.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Solomonidi, Nikolitsa
- Σολομωνίδη, Νικολίτσα
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/55189